The co-expression of CD39 and PD-1 endows these Tregs with potent suppressive capacity through adenosine-mediated and PD-1–dependent inhibitory pathways, promoting immune evasion, tumor progression, and resistance to immune checkpoint blockade (78). This evidence concerns the gene PDCD1 and neoplasm.